RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Guilin Medical University; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  2. Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07141056, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Diagnosed with unresectable HCC by pathology or imaging

    Inclusion criterion 7

    Pathologically confirmed HCC after curative surgery

    Inclusion criterion 17

    Pathological stage II or III (AJCC 8th edition)

    Inclusion criterion 18

    Diagnosed with resectable HCC by pathology or imaging

    Inclusion criterion 27

  3. Child-Pugh score > 7

    Exclusion criterion 7

  4. Will start adjuvant ICI therapy within 4-6 weeks after surgery

    Inclusion criterion 19

  5. ECOG performance status ≤ 1

    Inclusion criterion 4

    ECOG performance status ≤ 1

    Inclusion criterion 14

    ECOG performance status ≤ 1

    Inclusion criterion 24

  6. Has at least one measurable lesion (RECIST 1.1)

    Inclusion criterion 28

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07141056, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Cohort 1 (SOLACE-1):

Inclusion Criteria:

  • Age ≥ 18 years
  • Able to complete psychological questionnaires
  • Child-Pugh liver function class A
  • ECOG performance status ≤ 1
  • Signed informed consent
  • Expected survival > 3 months
  • Diagnosed with unresectable HCC by pathology or imaging
  • BCLC stage B or C
  • Has at least one measurable lesion (mRECIST)
  • About to receive first-line ICI treatment

Exclusion Criteria:

  • Currently taking antidepressant or anti-anxiety medications
  • Previous diagnosis of psychiatric disorders
  • Concurrent malignancy
  • Unable to complete psychological assessments
  • Previous systemic anti-tumor therapy
  • Symptomatic brain metastases
  • Child-Pugh score > 7

Cohort 2 (SOLACE-2):

Inclusion Criteria:

  • Age ≥ 18 years
  • Able to complete psychological questionnaires
  • Child-Pugh liver function class A
  • ECOG performance status ≤ 1
  • Signed informed consent
  • Expected survival > 3 months
  • Pathologically confirmed HCC after curative surgery
  • Pathological stage II or III (AJCC 8th edition)
  • Will start adjuvant ICI therapy within 4-6 weeks after surgery
  • Expected survival > 12 months

Exclusion Criteria:

  • Currently taking antidepressant or anti-anxiety medications
  • Previous diagnosis of psychiatric disorders
  • Concurrent malignancy
  • Unable to complete psychological assessments
  • Residual lesions after surgery
  • Child-Pugh score B or C

Cohort 3 (SOLACE-3):

Inclusion Criteria:

  • Age ≥ 18 years
  • Able to complete psychological questionnaires
  • Child-Pugh liver function class A
  • ECOG performance status ≤ 1
  • Signed informed consent
  • Expected survival > 3 months
  • Diagnosed with resectable HCC by pathology or imaging
  • Has at least one measurable lesion (RECIST 1.1)
  • About to receive neoadjuvant ICI treatment
  • Expected survival > 12 months

Exclusion Criteria:

  • Currently taking antidepressant or anti-anxiety medications
  • Previous diagnosis of psychiatric disorders
  • Severe cardiac, pulmonary, or renal dysfunction
  • Concurrent malignancy
  • Unable to complete psychological assessments
  • Previous systemic anti-tumor therapy
  • Symptomatic brain metastases
  • Child-Pugh score B or C

Quoted from ClinicalTrials.gov, NCT07141056, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07141056, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07141056